Adirondack Research & Management Increased By $476,118 Its Css Inds (CSS) Stake; 3 Bullish Analysts Covering Auris Medical Holding AG (EARS)

August 24, 2017 - By Kurt Siggers

Adirondack Research & Management Inc increased Css Inds Inc (CSS) stake by 12.44% reported in 2016Q4 SEC filing. Adirondack Research & Management Inc acquired 17,634 shares as Css Inds Inc (CSS)’s stock declined 2.61%. The Adirondack Research & Management Inc holds 159,410 shares with $4.32M value, up from 141,776 last quarter. Css Inds Inc now has $242.91 million valuation. The stock decreased 1.00% or $0.27 during the last trading session, reaching $26.71. About 17,657 shares traded. CSS Industries Inc (NYSE:CSS) has declined 5.69% since August 24, 2016 and is downtrending. It has underperformed by 22.39% the S&P500.

Among 3 analysts covering Auris Medical Holding AG (NASDAQ:EARS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Auris Medical Holding AG had 4 analyst reports since March 15, 2016 according to SRatingsIntel. On Tuesday, March 15 the stock rating was maintained by Jefferies with “Buy”. The stock of Auris Medical Holding AG (NASDAQ:EARS) earned “Buy” rating by Needham on Friday, August 19. The stock of Auris Medical Holding AG (NASDAQ:EARS) earned “Buy” rating by Roth Capital on Friday, June 30. See Auris Medical Holding AG (NASDAQ:EARS) latest ratings:

30/06/2017 Broker: Roth Capital Rating: Buy New Target: $4.5000 Initiate
13/04/2017 Broker: Roth Capital Rating: Buy Initiates Coverage On

It closed at $0.645 lastly. It is up 79.78% since August 24, 2016 and is downtrending. It has underperformed by 96.48% the S&P500.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical firm focused on the development of products for the treatment of inner ear disorders. The company has market cap of $22.21 million. The Company’s advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment from the United States Food and Drug Administration. It currently has negative earnings. The Company’s second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL).

Investors sentiment increased to 1.11 in 2016 Q4. Its up 0.17, from 0.94 in 2016Q3. It is positive, as 3 investors sold CSS shares while 25 reduced holdings. 9 funds opened positions while 22 raised stakes. 7.30 million shares or 1.23% more from 7.22 million shares in 2016Q3 were reported. State Common Retirement Fund holds 0% or 9,100 shares. Blackrock Mgmt Limited Liability reported 38,070 shares stake. D E Shaw And Co has 0% invested in CSS Industries Inc (NYSE:CSS) for 12,534 shares. Deutsche National Bank Ag holds 0% or 35,990 shares in its portfolio. Manufacturers Life The has invested 0% in CSS Industries Inc (NYSE:CSS). Retail Bank Of Montreal Can owns 0% invested in CSS Industries Inc (NYSE:CSS) for 372 shares. Acadian Asset Mgmt Limited Liability Com holds 0.01% or 38,971 shares in its portfolio. Walthausen Ltd Llc invested in 0.69% or 276,759 shares. Cornerstone Management Hldgs Limited Liability Company holds 0% of its portfolio in CSS Industries Inc (NYSE:CSS) for 16,025 shares. Delaware-based Blackrock Advisors Ltd Liability Corporation has invested 0% in CSS Industries Inc (NYSE:CSS). Blackrock Institutional Tru Na stated it has 0% of its portfolio in CSS Industries Inc (NYSE:CSS). Wells Fargo & Communications Mn has 5,351 shares for 0% of their portfolio. Brandywine Global Invest Management Limited Com holds 0% in CSS Industries Inc (NYSE:CSS) or 6,720 shares. Amp Capital Investors Ltd stated it has 7,713 shares or 0% of all its holdings. Rhumbline Advisers invested in 14,676 shares.